Last Updated : May 31, 2023
Details
Generic Name:
zanubrutinib
Project Status:
Active
Therapeutic Area:
Chronic lymphocytic leukemia /small lymphocytic lymphoma.
Manufacturer:
BeiGene Canada ULC
Call for patient/clinician input open:
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
PC0310-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of
adult patients with chronic lymphocytic leukemia (CLL).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of
adult patients with chronic lymphocytic leukemia (CLL).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | December 15, 2022 |
|---|---|
| Call for patient/clinician input closed | February 13, 2023 |
| Clarification: - Patient input submission received from Lymphoma Canada. | |
| Submission received | January 20, 2023 |
| Submission accepted | February 06, 2023 |
| Review initiated | February 07, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | April 25, 2023 |
| Deadline for sponsors comments | May 05, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | June 29, 2023 |
| Expert committee meeting (initial) | July 12, 2023 |
| Draft recommendation issued to sponsor | July 24, 2023 To July 26, 2023 |
| Draft recommendation posted for stakeholder feedback | August 03, 2023 |
| End of feedback period | August 18, 2023 |
Last Updated : May 31, 2023